This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.365. RemeGen Co's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.
As of today (2024-05-24), RemeGen Co's share price is HK$25.70. RemeGen Co's Median PS Value is HK$0.00. Therefore, RemeGen Co's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for RemeGen Co's Median PS Value or its related term are showing as below:
HKSE:09995's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
RemeGen Co Median PS Value Historical Data
The historical data trend for RemeGen Co's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RemeGen Co's Median PS Value
For the Biotechnology subindustry, RemeGen Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Price-to-Median-PS-Value falls into.
RemeGen Co Median PS Value Calculation
RemeGen Co's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
RemeGen Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1.365.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (HKSE:09995) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
RemeGen Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
25.70
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co Median PS Value Related Terms
Thank you for viewing the detailed overview of RemeGen Co's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09995 has been successfully added to your 